Post A Reply
my profile
login
|
register
|
search
|
faq
|
forum home
»
Allstocks.com's Bulletin Board
»
.11 and Up!
»
ACTC--NEWS
» Post A Reply
Post A Reply
Login Name:
Password:
Message Icon:
Message:
HTML is enabled.
UBB Code™ is enabled.
[QUOTE]Originally posted by BooDog: [QB] By: mailman2007 17 Oct 2007, 07:20 PM EDT Msg. 3508 of 3510 Jump to msg. # Dinsmore has plans for the heart of the initiativeMass High Tech: The Journal of New England Technology - by Lloyd Gray Mass High Tech Print Article Email Article Reprints RSS Feeds Add to Del.icio.us Digg This Though the picture in his mind was a wee bit fuzzy back then, Jonathan Dinsmore pretty much knew at age 10 what he wanted to be when he grew up. With a strong interest in science and biology, the leading choices were medical doctor, veterinarian, or medical researcher. "It was going to be (one of) those, but it was a moving target," he said recently with a chuckle. Several years, pedigreed schools and hard-earned degrees later, Dinsmore is now president, director and chief scientific officer of Mytogen Inc. Based in Charlestown and privately held, Mytogen develops cell-therapy products using stem cells. Its employees comprise experts specializing in clinical manufacturing of biologics, cell transplantation, and stem cell biology. Most of the attention the company receives these days is for its patented work using myoblasts -- also known as stem cells that form muscle -- to treat patients with congestive heart failure. After completing an initial safety and feasibility clinical trial, Mytogen, with U.S. Food and Drug Administration clearance, is now set to begin a second phase, this one aimed at confirming the initial results. Dinsmore estimates that with 5 million U.S. citizens experiencing heart complications, and with 500,000 new cases being diagnosed each year, market potential is in the billions. That potential led Advanced Cell Technology Inc. -- a company with locations in Worcester and Alameda, Cailf. -- to buy Mytogen for about $6 million. Executives from ACT, which has most of research operations in Worcester, have been meeting with Bay State Lt. Gov. Tim Murray to discuss how the developer of stem cell treatments could take advantage of a state plan to invest $1 billion in the life sciences sector, said the company's CEO William Caldwell. i found the link... http://cincinnati.bizjournals.com/masshightech/stories/2007/09/10/focus4.html [/QB][/QUOTE]
Instant Graemlins
Instant UBB Code™
What is UBB Code™?
Options
Disable Graemlins in this post.
*** Click here to review this topic. ***
Contact Us
|
Allstocks.com Message Board Home
© 1997 - 2021 Allstocks.com. All rights reserved.
Powered by
Infopop Corporation
UBB.classic™ 6.7.2